骨质疏松症治疗药物的经济学分析

被引：17

作者：

薛庆云

机构：

[1] 北京医院骨科

来源：

中华骨科杂志 | 2014年 / 34卷 / 01期

关键词：

D O I：

暂无

中图分类号：

R580 [];

学科分类号：

摘要：

<正>世界卫生组织对骨质疏松症（osteoporosis,OP）定义为:一种以骨量低下、骨微结构损害致骨脆性增加及易发生骨折为特征的全身性疾病[1]。美国国立卫生研究院（National Institutes of Health,NIH）提出OP是以骨强度下降、骨折风险增加为特征的骨骼系统疾病。二者均指出OP最终会增加骨折风险。因此,治疗OP的目标是降低骨折风险。根据病因,OP分为原发性和继发性两大类。本综述仅涉及原发性OP,其中主要以绝经后OP为主。2012年,卫生部发布的《防治骨质疏松知识要点》指出:OP是我国排名第四位的慢性疾病,也是中老年最常见的骨骼疾病[2]。OP的干预治疗是一项国家任务,同时OP的治疗

引用

共 22 条

[1]

唑来膦酸输注液与阿仑膦酸钠片预防骨质疏松性骨折的成本和收益比较 [J].

范长生 ;

董朝晖 ;

陶立波 .

中国药物经济学, 2009, (05) :11-24

[2]

北京老年妇女脊椎骨折的流行病学研究 [J].

徐苓 ;

秦明伟 ;

田均平 ;

赵熙和 ;

陈孝曙 ;

余卫 .

中国骨质疏松杂志, 1995, (01)

[3]

Cost-Effectiveness of Alendronate for the Treatment of Osteopenic Postmenopausal Women in Japan [J].

Moriwaki, Kensuke ;

Komaba, Hirotaka ;

Noto, Shinichi ;

Yanagisawa, Shinichiro ;

Takiguchi, Toru ;

Inoue, Hiroki ;

Toujo, Takeshi ;

Fukagawa, Masafumi ;

Takahashi, Hideaki E. .

JOURNAL OF BONE AND MINERAL RESEARCH, 2013, 28 (02) :395-403

[4]

Adherence with intravenous zoledronate and intravenous ibandronate in the united states medicare population [J].

Curtis, Jeffrey R. ;

Yun, Huifeng ;

Matthews, Robert ;

Saag, Kenneth G. ;

Delzell, Elizabeth .

ARTHRITIS CARE & RESEARCH, 2012, 64 (07) :1054-1060

[5]

Evidence to Inform Decision Makers in Thailand: A Cost-Effectiveness Analysis of Screening and Treatment Strategies for Postmenopausal Osteoporosis [J].

Kingkaew, Pritaporn ;

Maleewong, Usawadee ;

Ngarmukos, Chardpraorn ;

Teerawattananon, Yot .

VALUE IN HEALTH, 2012, 15 (01) :S20-S28

[6]

Cost-utility and budget impact analysis of primary prevention with alendronate of osteoporotic hip fractures in Catalonia [J].

Pueyo, Maria J. ;

Larrosa, Marta ;

Suris, Xavier ;

Garcia-Ruiz, Antonio J. .

REUMATOLOGIA CLINICA, 2012, 8 (03) :128-134

[7]

Cost-Effectiveness of Oral Bisphosphonates for Osteoporosis at Different Ages and Levels of Life Expectancy [J].

Pham, Annalise N. ;

Datta, Santanu K. ;

Weber, Thomas J. ;

Walter, Louise C. ;

Colon-Emeric, Cathleen S. .

JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2011, 59 (09) :1642-1649

[8]

The cost effectiveness of zoledronic acid 5?mg for the management of postmenopausal osteoporosis in women with prior fractures: evidence from Finland; Norway and the Netherlands.[J].R. Akehurst;N. Brereton;R. Ariely;T. Lusa;M. Groot;P. Foss;S. Boonen.Journal of Medical Economics.2011, 1

[9]

The Impact of Fewer Hip Fractures with Risedronate Versus Alendronate in the First Year of Treatment: Modeled German Cost-Effectiveness Analysis [J].

Thompson, Melissa ;

Pasquale, Margaret ;

Grima, Daniel ;

Moehrke, Werner ;

Kruse, Hans Peter .

VALUE IN HEALTH, 2010, 13 (01) :46-54

[10]

Cost–Effectiveness of Osteoporosis Screening Followed by Treatment: The Impact of Medication Adherence.[J]..Value in Health.2010, 4

← 1 2 3 →